Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testinga
References (27)
Fully human antibodies from transgenic mouse and phage display platforms
Curr Opin Immunol.
(2008)- et al.
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
J Immunol Methods
(2008) - et al.
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
J Immunol Methods
(2004) - et al.
Surface plasmon resonance and its use in biomolecular interaction analysis (BIA)
Curr Opin Struct Biol.
(1995) - et al.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial
Lancet
(2008) - et al.
Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards
Anal Biochem.
(2009) - et al.
Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies
J Pharm Biomed Anal.
(2005) - et al.
Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies
J Pharm Biomed Anal.
(2005) - et al.
Statistical analysis of radioligand assay data
Methods Enzymol.
(1975) Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Toxicology
(2005)
Ibuprofeninduced hypersensitivity syndrome
Transi Res.
(2010)
Monoclonal antibodies as innovative therapeutics
Curr Pharm Biotechnol
(2008)
Strategies and assays for the assessment of unwanted immunogenicity
J Immunotoxicol
(2006)
Cited by (66)
Application of DNA-based hydrogels as drug delivery system for immunomodulatory therapy
2023, Journal of Drug Delivery Science and TechnologyHypersensitivity Reactions to Monoclonal Antibodies
2018, Drug Allergy TestingIn vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies
2017, Toxicology in VitroHypersensitivity Reactions to Monoclonal Antibodies
2017, Drug Allergy TestingThe Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders
2018, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Overall, these data suggest that once the immunological mechanism leading to ADA production begins, it may be difficult to stop. Previous results have shown that IgE ADAs are detectable in a proportion of ADA-positive patients who have experienced HRs toward biologicals, including IFX.35,36 Several observations suggested that IgE-mediated HRs are more severe, occur earlier during the course of treatment, and occur more frequently during the second cycle of therapy.37
How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
2021, Frontiers in Immunology
- a
This work was presented in part as a poster at the Annual Scientific Meeting of the American College of Rheumatology, October 24–29, 2008, in San Francisco, California.
Copyright © 2010 Excerpta Medica Inc. All rights reserved.